Preclinical Evidence that Arctigenin Effectively and Selectively Targets Clear Cell Renal Cell Carcinoma Via Suppressing EGFR and RhoA.
Clear cell renal cell carcinoma (ccRCC) has poor clinical outcomes and necessitates new treatment options. Epidermal growth factor receptor (EGFR) is a potential therapeutic target, due to the associations with various carcinomas' progression. Arctigenin, a natural compound of Arctium lappa, has bee...
| Published in: | Nutrition & Cancer Vol. 75; no. 5; pp. 1373 - 1382 |
|---|---|
| Main Authors: | , , |
| Format: | pictorial research tables/charts Journal Article |
| Published: |
Taylor & Francis Ltd
2023
|
| Online Access: | View this record in EBSCOhost |